1. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer
6, 24–37 (2006).
2. Swann, J. B. & Smyth, M. J. Immune surveillance of tumors. J. Clin. Invest. 117, 1137–1146 (2007).
3. Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and
combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273–290 (2016).
4. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
5. Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724–740 (2017).
6. Dranoff, G. Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat. Rev. Immunol. 12,
61–66 (2011).
7. Carlsson, H. E., Schapiro, S. J., Farah, I. & Hau, J. Use of primates in research: a global overview. Am. J. Primatol. 63, 225–237 (2004).
8. Sackstein, R., Schatton, T. & Barthel, S. R. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer
immunotherapy. Lab. Invest. 97, 669–697 (2017).
9. Amsen, D., van Gisbergen, K., Hombrink, P. & van Lier, R. A. W. Tissue-resident memory T cells at the center of immunity to solid
tumors. Nat. Immunol. 19, 538–546 (2018).
10. Smazynski, J. & Webb, J. R. Resident memory-like tumor-infiltrating lymphocytes (TILRM): latest players in the immuno-oncology
repertoire. Front. Immunol. 9, 1741 (2018).
Scientific Reports |
(2020) 10:8414 | https://doi.org/10.1038/s41598-020-65488-x
www.nature.com/scientificreports/
www.nature.com/scientificreports
11. Slaney, C. Y., Kershaw, M. H. & Darcy, P. K. Trafficking of T cells into tumors. Cancer Res. 74, 7168–7174 (2014).
12. Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
Nat. Rev. Immunol. 17, 559–572 (2017).
13. Mullins, I. M. et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients
with stage III disease. Cancer Res. 64, 7697–7701 (2004).
14. Mlecnik, B. et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer.
Gastroenterology 138, 1429–1440 (2010).
15. Mikucki, M. E. et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular
checkpoints. Nat. Commun. 6, 7458 (2015).
16. Bronger, H. et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian
cancer. Br. J. Cancer 115, 553–563 (2016).
17. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome.
Nat. Rev. Cancer 12, 298–306 (2012).
18. Ishigaki, H. et al. Transplantation of iPS-derived tumor cells with a homozygous MHC haplotype induces GRP94 antibody
production in MHC-matched macaques. Cancer Res. 77, 6001–6010 (2017).
19. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
20. Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80 (2015).
21. Akari, H., Terao, K., Murayama, Y., Nam, K. H. & Yoshikawa, Y. Peripheral blood CD4+CD8+ lymphocytes in cynomolgus monkeys
are of resting memory T lineage. Int. Immunol. 9, 591–597 (1997).
22. Autissier, P., Soulas, C., Burdo, T. H. & Williams, K. C. Immunophenotyping of lymphocyte, monocyte and dendritic cell subsets in
normal rhesus macaques by 12-color flow cytometry: clarification on DC heterogeneity. J. Immunol. Methods 360, 119–128 (2010).
23. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and
maintenance. Annu. Rev. Immunol. 22, 745–763 (2004).
24. Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126,
3447–3452 (2016).
25. Kansy, B. A. et al. PD-1 status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer.
Cancer Res. 77, 6353–6364 (2017).
26. Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D. & Haribabu, B. Chemoattractant receptors BLT1 and CXCR3 regulate
antitumor immunity by facilitating CD8+ T cell migration into tumors. J. Immunol. 197, 2016–2026 (2016).
27. Skon, C. N. et al. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat.
Immunol. 14, 1285–1293 (2013).
28. Mackay, L. K. et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell
retention. J. Immunol. 194, 2059–2063 (2015).
29. Le Floc’h, A. et al. αEβ7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule
polarization and exocytosis. J. Exp. Med. 204, 559–570 (2007).
30. Franciszkiewicz, K. et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell
retention. Cancer Res. 69, 6249–6255 (2009).
31. Hombrink, P. et al. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells. Nat. Immunol.
17, 1467–1478 (2016).
32. Chen, L. & Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015).
33. Nam, K. et al. Peripheral blood extrathymic CD4+CD8+ T cells with high cytotoxic activity are from the same lineage as CD4+CD8−
T cells in cynomolgus monkeys. Int. Immunol. 12, 1095–1103 (2000).
34. Vujanovic, L. et al. CD56dim CD16− natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α.
Front. Immunol. 10, 14 (2019).
Acknowledgements
This work was supported by the Research Fund Granted by the President of Shiga University of Medical Science.
Author contributions
H.S., H.I., K. Terada, Y.A., Y.I., K.O. and T.H. designed the experiment, H.S., H.I., K. Todo, K. Terada, Y.A., Y.I.
and T.H. collected, analysed and interpreted the data, H.S. and T.H. wrote the manuscript, Y.A., Y.I., K.O. and T.H.
provided financial support and all authors reviewed the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-65488-x.
Correspondence and requests for materials should be addressed to T.H.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2020
Scientific Reports |
(2020) 10:8414 | https://doi.org/10.1038/s41598-020-65488-x
...
論文の公開元へ
